Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Study highlights role of CMV in patients with leukemia after bone marrow transplantation

Study highlights role of CMV in patients with leukemia after bone marrow transplantation

Recent studies on a small number of patients with leukemia treated with bone marrow transplantation have suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors may protect against relapse or even death after the transplant. [More]
LIF-treated muscle stem cells show promise in treatment of muscular dystrophy

LIF-treated muscle stem cells show promise in treatment of muscular dystrophy

Satellite cells are stem cells found in skeletal muscles. While transplantation of such muscle stem cells can be a potent therapy for degenerative muscle diseases such as Duchenne muscular dystrophy, these cells tend to lose their transplantation efficiency when cultured in vitro. [More]
Blocking c-Abl enzyme prevents Parkinson’s disease progression in mice

Blocking c-Abl enzyme prevents Parkinson’s disease progression in mice

Researchers at Johns Hopkins say they have gleaned two important new clues in the fight against Parkinson's disease: that blocking an enzyme called c-Abl prevents the disease in specially bred mice, and that a chemical tag on a second protein may signal the disorder's presence and progression. [More]
Scientists detect gene networks likely to be shared by all CLL patients

Scientists detect gene networks likely to be shared by all CLL patients

Research, involving scientists and doctors at the University of Southampton and Royal Bournemouth Hospital, has identified a network of genes that are likely to be shared by all patients who have chronic lymphocytic leukaemia (CLL). [More]
Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend. [More]
Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists at the Friedrich Miescher Institute for Biomedical Research and the University of Basel have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. [More]
Scientists discover how faulty genetic instructions contribute to development of AML

Scientists discover how faulty genetic instructions contribute to development of AML

Scientists have previously identified a series of genetic errors that commonly occur inside cancerous blood cells, but it hasn't been clear exactly how those genetic malfunctions create immature blood cells that overpopulate, crowd out healthy cells and spread in patients with acute myeloid leukemia or AML. [More]
Scientists streamline total synthesis of uncialamycin drug

Scientists streamline total synthesis of uncialamycin drug

A team led by Rice University scientists has improved the production of a potent anti-tumor antibiotic known as uncialamycin. [More]
New CAR-based therapy using combined cancer target could be effective for solid tumors

New CAR-based therapy using combined cancer target could be effective for solid tumors

Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. [More]
Telephone counseling can help make cancer genetic services more accessible to rural women

Telephone counseling can help make cancer genetic services more accessible to rural women

Ever since Angelina Jolie used cancer genetic counseling and testing to learn about her risk for hereditary breast and ovarian cancer, many other women have chosen to do the same. [More]
Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
Elevated levels of CXCL10 protein could help diagnose cGvHD in blood, bone marrow transplant patients

Elevated levels of CXCL10 protein could help diagnose cGvHD in blood, bone marrow transplant patients

A new study published today in the journal Blood has identified a protein that could diagnose chronic graft-versus-host disease (cGvHD), a serious, long-term complication that affects some patients after a blood and bone marrow transplant. [More]
Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry. [More]
Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe. [More]
Already-approved drugs can fight apoptosis evasion in cancer

Already-approved drugs can fight apoptosis evasion in cancer

Cancer cells don't die when they're supposed to. Animal and human bodies follow an orderly process of birthing new cells and killing old ones. But cancer cells escape programmed cell death, called apoptosis, and multiply uncontrollably. [More]
Interdisciplinary approach to improve cancer treatments

Interdisciplinary approach to improve cancer treatments

Whether it focuses on determining why certain cancers develop drug resistance, finding a way to improve individual's immune systems or better understanding cancer cell evolution, fundamental scientific research will "stand up to cancer" with three new awards from the National Science Foundation. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

We recently discovered a new form of an inherited deficiency of platelets, which is caused by mutations in the ETV6-gene. [More]
Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants. [More]
RNA editing enzyme ADAR1 may play role in regeneration of leukemia stem cells

RNA editing enzyme ADAR1 may play role in regeneration of leukemia stem cells

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. [More]
Advertisement